TRINTELLIX
Pronunciation: vor-tye-OX-e-teen


What it isSerotonin reuptake inhibitor with additional receptor modulation; depression.
Why this oneEvidence for improving cognitive symptoms of depression, and less sexual dysfunction than an SSRI.
What limits itNausea is dose-related and the commonest reason for stopping. CYP2D6-dependent, and cost is a barrier.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Major depressive disorder (MDD) | adult | 10 mg QD | 20 mg QD | 20 mg QD |
| MDD | CYP2D6 poor metabolizers | 10 mg QD | 10 mg QD | 10 mg QD |
Renal Undefined
Hepatic Undefined
5 mg/day may be considered for patients who do not tolerate higher doses
Available strengths
Pregnancy Limited data; third-trimester use may increase risk of PPHN and neonatal complications
Lactation No human milk data; weigh benefits against clinical need
| Strength | #/mo | generic $/mo | brand $/mo | CostPlus | |
|---|---|---|---|---|---|
| 5 mg | tab | 30 qd | — | $515.90 | not offered |
| 10 mg | tab | 30 qd | — | $515.92 | not offered |
| 20 mg | tab | 30 qd | — | $515.99 | not offered |
Generic entry2027 est.
⚠ BOXED WARNING
Legacy pregnancy categoryC
Defining liabilityNausea, sexual effects and serotonin toxicity are the principal concerns.
Provisional washout figures
Elevating mechanismSRI
Non-elevating action5-HT1A agonist; 5-HT1B partial agonist; 5-HT3/5-HT7 antagonist
Exposure dependenceTherapeutic exposure; severe toxicity requires meaningful MAO-A inhibition
Washout BEFORE an MAOI21 days
Evidence confidenceHigh
InterpretationClinically significant SRI despite multimodal receptor marketing. A second SRI generally represents therapeutic duplication/additive adverse effects, not the classic life-threatening interaction.
Open Vortioxetine in the interactive console ↗